Pub Date : 2021-02-01DOI: 10.37532/2041-6792.2021.11(1).10-18
V. Trieu, Saran Saund, P. Rahate, Viljay B. Barge, K. Nalk, H. Windlass, F. Uckun
Our COVID-19 drug candidate ARTIVedaTM/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF-β targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVedaTM in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase 4 study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score=2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score=1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (p=0.028, Fisher’s exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score=4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (p=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF-β pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.
{"title":"Targeting TGF-beta pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19","authors":"V. Trieu, Saran Saund, P. Rahate, Viljay B. Barge, K. Nalk, H. Windlass, F. Uckun","doi":"10.37532/2041-6792.2021.11(1).10-18","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(1).10-18","url":null,"abstract":"Our COVID-19 drug candidate ARTIVedaTM/PulmoHeal is a novel gelatin capsule formulation of the Artemisia extract Ayurveda for oral delivery of TGF-β targeting anti-malaria phytomedicine Artemisinin with documented anti-inflammatory and anti-SARS-CoV-2 activity. Here we report the safety and efficacy of ARTIVedaTM in adult COVID-19 patients with symptomatic mild-moderate COVID-19, who were treated in a randomized, open-label Phase 4 study in Bangalore, Karnataka, India (Clinical Trials Registry India identifier: CTRI/2020/09/028044). ARTIVeda showed a very favorable safety profile, and the only ARTIVeda-related adverse events were transient mild rash and mild hypertension. Notably, ARTIVeda, when added to the SOC, accelerated the recovery of patients with mild-moderate COVID-19. While all patients were symptomatic at baseline (WHO score=2-4), 31 of 39 (79.5%) of patients treated with ARTIVeda plus SOC became asymptomatic (WHO score=1) by the end of the 5-day therapy, including 10 of 10 patients with severe dry cough 7 of 7 patients with severe fever. By comparison, 12 of 21 control patients (57.1%) treated with SOC alone became asymptomatic on day 5 (p=0.028, Fisher’s exact test). This clinical benefit was particularly evident when the treatment outcomes of hospitalized COVID-19 patients (WHO score=4) treated with SOC alone versus SOC plus ARTIVeda were compared. The median time to becoming asymptomatic was only 5 days for the SOC plus ARTIVeda group (N=18) but 14 days for the SOC alone group (N=10) (p=0.004, Log-rank test). These data provide clinical proof of concept that targeting the TGF-β pathway with ARTIVeda may contribute to a faster recovery of patients with mild-moderate COVID-19 when administered early in the course of their disease.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"8 1","pages":"10-18"},"PeriodicalIF":0.0,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89267589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(2).49-50
J. Stewert
Allergic rhinitis is a chronic disease linked to asthma and conjunctivitis. It is typically a chronic condition that goes undetected in primary care. Popular symptoms include nasal cough, nasal itch, rhinorrhea, and sneezing. To diagnose allergic rhinitis, a comprehensive medical history, physical examination, and allergen skin testing are all required.
{"title":"A Prospective on Allergic Rhinitis","authors":"J. Stewert","doi":"10.37532/2041-6792.2021.11(2).49-50","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(2).49-50","url":null,"abstract":"Allergic rhinitis is a chronic disease linked to asthma and conjunctivitis. It is typically a chronic condition that goes undetected in primary care. Popular symptoms include nasal cough, nasal itch, rhinorrhea, and sneezing. To diagnose allergic rhinitis, a comprehensive medical history, physical examination, and allergen skin testing are all required.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"181 1","pages":"49-50"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73742868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(1).31
J. Stewert
Cladribine reaches the cell via proteins that hold nucleoside. Cladribine is activated within the cell by three subsequent phosphorylations, the first being deoxycytidine kinase. The enzyme 5'-nucleotidase (5'-NTase), active cladribine can be inactivated by dephosphorylation.
{"title":"Use of Cladribine for multiple sclerosis treatment: An image article","authors":"J. Stewert","doi":"10.37532/2041-6792.2021.11(1).31","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(1).31","url":null,"abstract":"Cladribine reaches the cell via proteins that hold nucleoside. Cladribine is activated within the cell by three subsequent phosphorylations, the first being deoxycytidine kinase. The enzyme 5'-nucleotidase (5'-NTase), active cladribine can be inactivated by dephosphorylation.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"142 1","pages":"31-31"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79843493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(2).41-48
Pınar Ellergezen, A. Alp, S. Çavun, Gülce Sevdar Çeçen, A. Macunluoglu
Objective: To investigate the relationship between vitamin D levels and inflammatory cytokine levels in patients with Fibromyalgia Syndrome (FMS). Materials and Methods: 29 women with FMS who were diagnosed according to American College of Rheumatology (ACR) 2010 fibromyalgia diagnostic criteria and 25 healthy women as the control group was included in the study. Serum levels of vitamin D, Vitamin D Receptor (VDR) and Vitamin D Binding Protein (VDBP), and inflammatory cytokines (IL-2, IL-4, IL-6, IL-12, IFN-γ) were analyzed using by ELISA method. Widespread body pain, fatigue, morning stiffness, cognitive symptoms, somatic symptoms, Fibromyalgia Impact Questionnaire (FIQ) scores were evaluated in patients with FMS. Results: Vitamin D, VDR, and VDBP levels were found to be higher in the healthy individuals compared to the patients with FMS (p<0.001, p<0.002, p<0.001, respectively). Correspondingly, pro-inflammatory (IL-2, IL-12, IFN-γ), anti-inflammatory (IL-4), and both pro and anti-inflammatory (IL-6) cytokine levels of the control group were higher than the patients with FMS (p<0.001, p<0.006, p<0.004, p<0.001, p<0.049, respectively). Conclusion: Low vitamin D levels in FMS may negatively affect the release of inflammatory cytokines and this functional relationship may be in the etiology of this chronic pain disorder
{"title":"Low Vitamin D Levels can Effect the Balance of Immun Mediators in Fibromyalgia Syndrome Objective","authors":"Pınar Ellergezen, A. Alp, S. Çavun, Gülce Sevdar Çeçen, A. Macunluoglu","doi":"10.37532/2041-6792.2021.11(2).41-48","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(2).41-48","url":null,"abstract":"Objective: To investigate the relationship between vitamin D levels and inflammatory cytokine levels in patients with Fibromyalgia Syndrome (FMS). Materials and Methods: 29 women with FMS who were diagnosed according to American College of Rheumatology (ACR) 2010 fibromyalgia diagnostic criteria and 25 healthy women as the control group was included in the study. Serum levels of vitamin D, Vitamin D Receptor (VDR) and Vitamin D Binding Protein (VDBP), and inflammatory cytokines (IL-2, IL-4, IL-6, IL-12, IFN-γ) were analyzed using by ELISA method. Widespread body pain, fatigue, morning stiffness, cognitive symptoms, somatic symptoms, Fibromyalgia Impact Questionnaire (FIQ) scores were evaluated in patients with FMS. Results: Vitamin D, VDR, and VDBP levels were found to be higher in the healthy individuals compared to the patients with FMS (p<0.001, p<0.002, p<0.001, respectively). Correspondingly, pro-inflammatory (IL-2, IL-12, IFN-γ), anti-inflammatory (IL-4), and both pro and anti-inflammatory (IL-6) cytokine levels of the control group were higher than the patients with FMS (p<0.001, p<0.006, p<0.004, p<0.001, p<0.049, respectively). Conclusion: Low vitamin D levels in FMS may negatively affect the release of inflammatory cytokines and this functional relationship may be in the etiology of this chronic pain disorder","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"6 1","pages":"41-48"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84705031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(1).26-30
M. J. Iqbal, Mazhar Ali, Rizwan Ghafoor, A. khan, M. M. Raza
Aim and Objective: The objective of this case series is to evaluate the effectiveness of Tramadol according to prescribe-rs and patient's feedback. Methodology: A cross-sectional study to assess pain management practice among patients from different hospitals of Punjab. We conducted this study and collect data from August 2020 to October 2020. A total of 740 patients were included in our study and fulfilled the inclusion criteria. Results: In our results, we find that consumption of opioids in different pain types and concluded that tramadol is the most used opioid among all other opioids. We also found its stability, safety, and efficacy parameters. We confirmed from our study tramadol is used mostly to treat acute musculoskeletal pain. Conclusion: We concluded that tramadol has lower dependency as compare to other recent opioids and have more benefits.
{"title":"Study the different incidences of Tramadol in different cities of Punjab, Pakistan","authors":"M. J. Iqbal, Mazhar Ali, Rizwan Ghafoor, A. khan, M. M. Raza","doi":"10.37532/2041-6792.2021.11(1).26-30","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(1).26-30","url":null,"abstract":"Aim and Objective: The objective of this case series is to evaluate the effectiveness of Tramadol according to prescribe-rs and patient's feedback. Methodology: A cross-sectional study to assess pain management practice among patients from different hospitals of Punjab. We conducted this study and collect data from August 2020 to October 2020. A total of 740 patients were included in our study and fulfilled the inclusion criteria. Results: In our results, we find that consumption of opioids in different pain types and concluded that tramadol is the most used opioid among all other opioids. We also found its stability, safety, and efficacy parameters. We confirmed from our study tramadol is used mostly to treat acute musculoskeletal pain. Conclusion: We concluded that tramadol has lower dependency as compare to other recent opioids and have more benefits.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"39 1","pages":"26-30"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87842860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(1).1-9
F. Uckun, C. Orhan, I. Ozercan, N. Şahin, Joy Powell, Natalie M. Pizzimenti, A. VolkMichael, K. Şahin
Severe viral sepsis of coronavirus disease 2019 (COVID-19) is associated with a Cytokine Release Syndrome (CRS) and a high case fatality rate due to the development of Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure in high-risk COVID-19 patients, including cancer patients undergoing chemotherapy. Here, we demonstrate that our COVID-19 drug candidate Rejuveinix (RJX) exhibits potent protective anti-inflammatory activity in the LPS-GalN mouse model of fatal sepsis and multi-organ failure at a dose level >10x lower than its maximum tolerated dose (MTD) for human subjects. In BALB/c mice challenged with an otherwise invariably fatal dose of LPS-GalN, prophylactic administration of 0.7 mL/kg RJX (Human equivalent dose=0.057 mL/ kg), corresponding to 7.5% of its clinical Maximum Tolerated Dose (MTD), prevented the cytokine storm, mitigated the oxidative stress and inflammatory tissue injury in lungs, liver, and heart, and significantly improved the survival outcome. Furthermore, RJX increased the levels of antioxidant enzymes SOD, CAT, and GSH-Px, and reduced oxidative stress in the brain. These results indicate that RJX has clinical potential as a prophylactic anti-inflammatory agent against severe sepsis, including viral sepsis in COVID-19 patients.
{"title":"Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis","authors":"F. Uckun, C. Orhan, I. Ozercan, N. Şahin, Joy Powell, Natalie M. Pizzimenti, A. VolkMichael, K. Şahin","doi":"10.37532/2041-6792.2021.11(1).1-9","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(1).1-9","url":null,"abstract":"Severe viral sepsis of coronavirus disease 2019 (COVID-19) is associated with a Cytokine Release Syndrome (CRS) and a high case fatality rate due to the development of Acute Respiratory Distress Syndrome (ARDS) and multi-organ failure in high-risk COVID-19 patients, including cancer patients undergoing chemotherapy. Here, we demonstrate that our COVID-19 drug candidate Rejuveinix (RJX) exhibits potent protective anti-inflammatory activity in the LPS-GalN mouse model of fatal sepsis and multi-organ failure at a dose level >10x lower than its maximum tolerated dose (MTD) for human subjects. In BALB/c mice challenged with an otherwise invariably fatal dose of LPS-GalN, prophylactic administration of 0.7 mL/kg RJX (Human equivalent dose=0.057 mL/ kg), corresponding to 7.5% of its clinical Maximum Tolerated Dose (MTD), prevented the cytokine storm, mitigated the oxidative stress and inflammatory tissue injury in lungs, liver, and heart, and significantly improved the survival outcome. Furthermore, RJX increased the levels of antioxidant enzymes SOD, CAT, and GSH-Px, and reduced oxidative stress in the brain. These results indicate that RJX has clinical potential as a prophylactic anti-inflammatory agent against severe sepsis, including viral sepsis in COVID-19 patients.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"17 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84699127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(1).19-25
J. Cheema, A. Salam, Aqil Khan, M. Z. Zafar
Objective: To assess AIDS awareness among the educated community of Lahore and Gujranwala, Pakistan. Design: Cross-sectional qualitative study. Methods: A questionnaire was designed with the study objectives and distributed to the educated community of Lahore and Gujranwala, gathering the information including, demographic details (name, age, sex, and level of education), HIV-related knowledge (modes of transmission, prevention, and treatment), attitudes and risk perception. The reason for selecting the educated community was that they are the pioneer to educate and council illiterate communities. The results were recorded and data were analyzed. Results: 68.78% respondents have knowledge about the basics of AIDS, including, causative agent, and origin, behavior of society towards AIDS patients and incubation period of HIV/AIDS. 69.2% respondents have correct knowledge about modes of transmission of HIV/AIDS. 78.75% respondents are aware of prevention and treatment. 81% respondents think that media is playing some role in awareness about AIDS. Conclusion: Although respondents demonstrated a high level of knowledge concerning AIDS and HIV, considerable misconceptions were also noted. A need was felt to enhance awareness programs among educated community members of two different cities. There is an intense need for a mass media campaign against AIDS.
{"title":"To assess AIDS awareness among the educated community of Lahore and Gujranwala, Pakistan","authors":"J. Cheema, A. Salam, Aqil Khan, M. Z. Zafar","doi":"10.37532/2041-6792.2021.11(1).19-25","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(1).19-25","url":null,"abstract":"Objective: To assess AIDS awareness among the educated community of Lahore and Gujranwala, Pakistan. Design: Cross-sectional qualitative study. Methods: A questionnaire was designed with the study objectives and distributed to the educated community of Lahore and Gujranwala, gathering the information including, demographic details (name, age, sex, and level of education), HIV-related knowledge (modes of transmission, prevention, and treatment), attitudes and risk perception. The reason for selecting the educated community was that they are the pioneer to educate and council illiterate communities. The results were recorded and data were analyzed. Results: 68.78% respondents have knowledge about the basics of AIDS, including, causative agent, and origin, behavior of society towards AIDS patients and incubation period of HIV/AIDS. 69.2% respondents have correct knowledge about modes of transmission of HIV/AIDS. 78.75% respondents are aware of prevention and treatment. 81% respondents think that media is playing some role in awareness about AIDS. Conclusion: Although respondents demonstrated a high level of knowledge concerning AIDS and HIV, considerable misconceptions were also noted. A need was felt to enhance awareness programs among educated community members of two different cities. There is an intense need for a mass media campaign against AIDS.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"83 1","pages":"19-25"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88610376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(2).32-36
Wen Wang, L. Zhong, Wen-Dao Li, Shijing Wu, Hongmei Song
nucleotide-binding domain region of the NOD2/CARD15 gene. We reported the case of a patient with a typical triad of rash, arthritis, and uveitis. Sanger sequencing indicated a NOD2 missense variant (c.1759 C >T, p.R587C) in the patient that was inherited from the mother. After treatment with methotrexate, a TNF-α inhibitor, and corticosteroids, the patient’s clinical symptoms and inflammatory indicators remained uncontrolled. In the meantime, the patient experienced multiple side effects, such as hypertension and growth retardation attributed to prolonged use of corticosteroids. After treatment with thalidomide, the condition was controlled without recurrence or side effects, and corticosteroids were stopped as soon as possible. This report suggests that thalidomide may be an effective drug for BS treatment.
{"title":"Thalidomide may be an effective medicine for Blau Syndrome","authors":"Wen Wang, L. Zhong, Wen-Dao Li, Shijing Wu, Hongmei Song","doi":"10.37532/2041-6792.2021.11(2).32-36","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(2).32-36","url":null,"abstract":"nucleotide-binding domain region of the NOD2/CARD15 gene. We reported the case of a patient with a typical triad of rash, arthritis, and uveitis. Sanger sequencing indicated a NOD2 missense variant (c.1759 C >T, p.R587C) in the patient that was inherited from the mother. After treatment with methotrexate, a TNF-α inhibitor, and corticosteroids, the patient’s clinical symptoms and inflammatory indicators remained uncontrolled. In the meantime, the patient experienced multiple side effects, such as hypertension and growth retardation attributed to prolonged use of corticosteroids. After treatment with thalidomide, the condition was controlled without recurrence or side effects, and corticosteroids were stopped as soon as possible. This report suggests that thalidomide may be an effective drug for BS treatment.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"40 1","pages":"32-36"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80785831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37532/2041-6792.2021.11(2).37-40
Ruth Lourens
Compassion Fatigue (CF) in healthcare workers was first coined by Carla Joinson in 1992, in almost three decades following copious amounts of research have been done on this subject. Findings of the research indicate an astronomical growing problem, yet very little has been done to curb this problem. Today researchers agree that one of the major causes of compassion fatigue in nursing is a lack of education. Nurse’s education doesn’t include subjects dealing with self-care, burnout, vicarious trauma, and CF. Francoise Mathieu, an expert on CF, notes that after completing her degree and several courses in three different countries, she had not once heard the words self-care, burnout, and CF, and nor did I until it happened to me.
{"title":"Burnout, Compassion Fatigue and Vicarious Trauma","authors":"Ruth Lourens","doi":"10.37532/2041-6792.2021.11(2).37-40","DOIUrl":"https://doi.org/10.37532/2041-6792.2021.11(2).37-40","url":null,"abstract":"Compassion Fatigue (CF) in healthcare workers was first coined by Carla Joinson in 1992, in almost three decades following copious amounts of research have been done on this subject. Findings of the research indicate an astronomical growing problem, yet very little has been done to curb this problem. Today researchers agree that one of the major causes of compassion fatigue in nursing is a lack of education. Nurse’s education doesn’t include subjects dealing with self-care, burnout, vicarious trauma, and CF. Francoise Mathieu, an expert on CF, notes that after completing her degree and several courses in three different countries, she had not once heard the words self-care, burnout, and CF, and nor did I until it happened to me.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"27 1","pages":"37-40"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87274206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.37532/2041-6792.2020.10(3).169
Kranthi Kumar, M. Das, Gautam Singh, M. L. Madhu, Jeswin M Thomas, A. Prabha
Context and Aim: Formocresol has been used as the material of choice (gold standard) for pulpotomy procedures because of the ease of use but was discouraged due to its potential immune sensitization and mutagenic effects. Laser irradiation was first applied for pulpotomy procedure in the year 1985. Recently, diode lasers have been used for pulpotomy in primary teeth and have shown clinical success rates comparable to formocresol. The present in-vivo study was carried out to compare the clinical and radiographic success rates of Mineral Trioxide Aggregate (MTA) alone and diode laser-MTA for pulpotomy in human primary molars. Materials and Methods: The present study was a randomized clinical trial in design wherein forty primary teeth requiring pulpotomy treatment which met the selection criteria (clinical and radiographic) were divided into two groups, group 1 (n=20) wherein the pulpotomy was performed with MTA alone and group 2 (n=20) wherein laser-assisted pulpotomy was performed with MTA (L-MTA). The patients were recalled after 3, 6 and 9 months respectively and evaluated clinically and radiographically. Statistical Analysis Used: The data were analyzed using the Statistical Package for the Social Sciences (SPSS) Version 22 (IBM corporation, Washington DC, United States). Descriptive statistics were used to analyze the data while the Pearson's correlation coefficient test was used to analyze the statistical correlation between the overall success rates observed in the clinical and radiographic findings of both the groups. p<0.05 was considered statistically significant. Results: The clinical success rate in the MTA group was 90%, 84.21% and 88.23% at 3, 6 and 9 months respectively with no clinical signs or, symptoms reported at the said follow-up visits while the radiographic success rate was found to be 85%, 84.21%, and 82.3% respectively. On the contrary, the clinical success rate in the L-MTA group was found to be 95%, 94.74% and 94.44% at 3, 6 and 9 months respectively with the radiographic success rate reported being 90%, 89.47%, and 88.89% respectively. Conclusion: The combination of diode laser and MTA yielded better clinical and radiographic success rates over the pulpotomy procedures done with the help of MTA alone.
{"title":"Comparative Evaluation of MTA Pulpotomy and Laser-Assisted MTA Pulpotomy in Primary Teeth: A Randomized Clinical Trial","authors":"Kranthi Kumar, M. Das, Gautam Singh, M. L. Madhu, Jeswin M Thomas, A. Prabha","doi":"10.37532/2041-6792.2020.10(3).169","DOIUrl":"https://doi.org/10.37532/2041-6792.2020.10(3).169","url":null,"abstract":"Context and Aim: Formocresol has been used as the material of choice (gold standard) for pulpotomy procedures because of the ease of use but was discouraged due to its potential immune sensitization and mutagenic effects. Laser irradiation was first applied for pulpotomy procedure in the year 1985. Recently, diode lasers have been used for pulpotomy in primary teeth and have shown clinical success rates comparable to formocresol. The present in-vivo study was carried out to compare the clinical and radiographic success rates of Mineral Trioxide Aggregate (MTA) alone and diode laser-MTA for pulpotomy in human primary molars. Materials and Methods: The present study was a randomized clinical trial in design wherein forty primary teeth requiring pulpotomy treatment which met the selection criteria (clinical and radiographic) were divided into two groups, group 1 (n=20) wherein the pulpotomy was performed with MTA alone and group 2 (n=20) wherein laser-assisted pulpotomy was performed with MTA (L-MTA). The patients were recalled after 3, 6 and 9 months respectively and evaluated clinically and radiographically. Statistical Analysis Used: The data were analyzed using the Statistical Package for the Social Sciences (SPSS) Version 22 (IBM corporation, Washington DC, United States). Descriptive statistics were used to analyze the data while the Pearson's correlation coefficient test was used to analyze the statistical correlation between the overall success rates observed in the clinical and radiographic findings of both the groups. p<0.05 was considered statistically significant. Results: The clinical success rate in the MTA group was 90%, 84.21% and 88.23% at 3, 6 and 9 months respectively with no clinical signs or, symptoms reported at the said follow-up visits while the radiographic success rate was found to be 85%, 84.21%, and 82.3% respectively. On the contrary, the clinical success rate in the L-MTA group was found to be 95%, 94.74% and 94.44% at 3, 6 and 9 months respectively with the radiographic success rate reported being 90%, 89.47%, and 88.89% respectively. Conclusion: The combination of diode laser and MTA yielded better clinical and radiographic success rates over the pulpotomy procedures done with the help of MTA alone.","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"60 1","pages":"67-74"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88320108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：